Natixis Advisors LLC Grows Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Natixis Advisors LLC increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 61.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,697 shares of the company’s stock after purchasing an additional 8,606 shares during the quarter. Natixis Advisors LLC’s holdings in Vaxcyte were worth $2,594,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after buying an additional 8,685 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Vaxcyte by 392.4% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock valued at $3,046,000 after acquiring an additional 32,149 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after acquiring an additional 498,359 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Vaxcyte in the 1st quarter worth approximately $1,288,000. Finally, Tri Locum Partners LP purchased a new position in Vaxcyte in the 2nd quarter worth approximately $8,559,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the sale, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 1.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. This trade represents a 8.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 102,464 shares of company stock worth $11,455,576 in the last three months. 3.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on PCVX shares. Bank of America increased their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Mizuho boosted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Jefferies Financial Group raised their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, BTIG Research increased their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $147.50.

Vaxcyte Stock Performance

Vaxcyte stock opened at $88.54 on Monday. The company has a market capitalization of $11.04 billion, a price-to-earnings ratio of -19.25 and a beta of 1.01. The company’s 50 day simple moving average is $107.89 and its 200-day simple moving average is $89.57. Vaxcyte, Inc. has a 1 year low of $48.24 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the business earned ($0.91) EPS. Equities analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.